N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline|147266-92-0|-陌孚医药/Medlife

您当前的位置：

N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline

目录号: PL10517

CAS No. :147266-92-0

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline
中文别名	N-Boc-反式-4-羟基-D-脯氨酸;BOC-D-反式-羟脯氨酸;N-叔丁氧羰基-反式-4-羟基-D-脯氨酸;BOC-反式-4-羟基-D-脯氨酸;(2R,4S)-2-羧基-4羟基-N-BOC-吡咯烷;(2R,4S)-1-[(叔丁氧基)羰基]-4-羟基吡咯烷-2-羧酸;N-BOC-反式-4-羟基-D-脯氨酸 1G;N-BOC-反式-4-羟基-D-脯氨酸,99%
英文名称	N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline
英文别名	(2R,4S)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid;BOC-D-PRO(4-HYDROXY)-OH;BOC-D-HYP-OH;BOC-TRANS-4-HYDROXY-D-PROLINE;N-T-BOC-TRANS-4-HYDROXY-D-PROLINE;N-ALPHA-T-BUTOXYCARBONYL-D-HYDROXYPROLINE;N-Boc-trans-4-Hydroxy-D-proline;N-BOC-CIS-7-HYDROXY-D-PROLINE;(2R,4S)-N-ALPHA-T-BUTOXYCARBONYL-4-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID;Boc-trans-D-Hyp-OH;(4S)-1-(tert-butoxycarbonyl)-4-hydroxy-D-proline;(Tert-Butoxy)Carbonyl D-trans-Hyp-OH;Boc-trans-4-hydroxy-D-proline≥ 95% (NMR);(2R,4S)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid;7K1V4SDL4L;(2R,4S)-1-rel-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid;N-Boc-4-hydroxy-D-proline, trans-;N-Boc-trans-4-hydroxy-d-prolne
Cas No.	147266-92-0
分子式	C₁₀H₁₇NO₅
分子量	231.25
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline 是不可降解 (non-cleavable) 的 ADC linker，用于合成抗体偶联药物 (ADCs)。N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline 也是一个基于烷基链 (alkyl chain) 的 PROTAC linker，可用于合成 PROTAC。
生物活性	N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
性状	Solid
IC50 & Target[1][2]	Non-cleavable
体外研究(In Vitro)	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

溶解度数据	In Vitro: DMSO : 100 mg/mL (432.43 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品